Trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2, has revolutionized the treatment landscape for HER2-positive breast cancer, significantly improving patient outcomes in both early-stage and metastatic settings [1,4]. This evidence concerns the gene ERBB2 and breast carcinoma.